Scleritis complicating zoledronic acid infusion

Clinical Lymphoma and Myeloma

Volumn 7, Issue 2, 2006, Pages 145-147

  Benderson, David ^a   Karakunnel, Joyson ^a   Kathuria, Sajeev ^a   Badros, Ashraf ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Bisphosphonates; Multiple myeloma; Ocular inflammation

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PHENYLEPHRINE; PREDNISOLONE ACETATE; THALIDOMIDE; ZOLEDRONIC ACID;

AGED; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; CONTINUOUS INFUSION; DRUG POTENCY; DRUG SUBSTITUTION; HUMAN; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK BENEFIT ANALYSIS; SCLERITIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

EID: 33750199047     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.053     Document Type: Article

References (27)

1. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20:3719-3736.
2. Takeyama S, Shinoda H. Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium 2003; 13:115-121.
3. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996; 14:158-170.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534.
5. Siris ES. Bisphosphonates and iritis. Lancet 1993; 341:436-437.
6. Adverse drug reactions in Canada. Bisphosphonates and ocular disorders. Can Fam Physician 2004; 50:422-424.
7. Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med 2003; 348:1187-1188.
8. Macarol V, Fraunfelder FT. Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 1994; 118:220-224.
9. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21:2732-2739.
10. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9:2643-2658.
11. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005; 39:668-677.
12. O'Donnell NP, Rao GP, Aguis-Fernandez A. Paget's disease: ocular complications of disodium pamidronate treatment. Br J Clin Pract 1995; 49:272-273.
13. Leung S, Ashar BH, Miller RG. Bisphosphonate-associated scleritis: a case report and review. South Med J 2005; 98:733-735.
14. Haverbeke G, Pertile G, Claes C, et al. Posterior uveitis: an underrecognized adverse effect of pamidronate: 2 case reports. Bull Soc Belge Ophtalmol 2003:71-76.
15. Diphosphonates: ocular risks. Prescrire Int 2005; 14:179.
16. Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003; 135:219-222.
17. Vinas G, Olive A, Holgado S, et al. Episcleritis secondary to risedronate. Med Clin (Barc) 2002; 118:598-599.
18. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004; 111:1275-1279.
19. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005; 139:101-111.
20. Watson PC, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res 2004; 78:609-623.
21. Bernauer W, Daicker B. Inflammatory cellular infiltration in scleritis. Ophthalmologe 1995; 92:46-48.
22. Zierhut M, Denk PO, Klein R, et al. Autoantibody pattern in scleritis and episcleritis. Ophthalmologe 1997; 94:157-160.
23. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96:384-392.
24. Mariani S, Muraro M, Pantaleoni F, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19:664-670.
25. Pecherstorfer M, Jilch R, Sauty A, et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000; 15:147-154.
26. Conti L, Casetti R, Cardone M, et al. Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 2005; 174:252-260.
27. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116:94-99.